

12<sup>th</sup> Annual  
**PHARMA** **IIPR**  
I N D I A 2 0 2 3

**1-3 March 2023**  
Novotel Hotel Mumbai International Airport, Mumbai

Country's Largest  
**Global Pharma IP Conference**



# About

## Pharma IPR Conference

Pharma IPR Conference, now in its 12th edition, is organized by world leaders' in B2B events Informa Markets, who are also the makers of CPHI. Pharma IPR Conference is the only conference in India's pharmaceutical industry that focuses on Intellectual Property. It will be held in Mumbai from 1-3 March, 2023. The aim of this conference is to bring together all stakeholders in the pharma sector to discuss and deliberate on the challenges faced by innovators and how they can protect their valuable innovations by effective IP management.

Driven by powerful content and unmatched speaker profiles, the 12th Annual Pharma IPR Conference promises to provide an exceptional opportunity to bring key stakeholders, IP Attorneys, and Counsels from across the globe to the same platform. Leading global IP experts will discuss, deliberate, and share their thoughts on achieving the next phase of growth in the Pharma IPR space.



# Glimpses from past editions



Speed Networking



Conference Proceedings



Pharma IPR Fraternity



Panel Discussion



Cocktails



# Testimonials

We have witnessed more and more attendees every year, gives us a great opportunity to build relation with various pharmaceuticals companies. Here there are excellent speakers providing insights on critical key challenges.

**Alejandro Menchaca**  
**McAdrews, Held & Mallboy Ltd.**

**Anju Khanna**  
**Lall & Sethi**

I am very excited to be here today at Pharma IPR. The quality of session is very good. It's a good collection of people. I can see myself coming next year again.

This is my 4th time attending Pharma IPR. The quality of subject & organization has improved. I am very happy and satisfied.

**Dr. Mohan Dewan**  
**Principle, R.K. Dewan & Co.**

**Nevin Jacob Koshy**  
**United Trademark & Patent Service**

My experience being in this conference is good. Got to meet new faces and interact and learn about the markets with greatest mind of Pharma IPR Industry. I would definitely recommend this conference.

# Who should Partner?

National and International Law Firms

IP Software Companies

Legal/ IP Consultants

Patent Search Companies

# Who will you meet

*In-House Counsel and Executives from Pharmaceutical and Biotech Companies, including:*

General Counsel


Head of IP

Head of Patent Litigation

Head of Legal/Legal Affairs

- Principal Patent Examiner
- Head of Global Strategy
- IP and Portfolio Management
- R&D Patent Manager
- Patent Counsel
- Patent Litigation Counsel
- Division Counsel
- Intellectual Property and Patent Law

VP-Intellectual Property





## Why Partner

Pharma IPR Conferences provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners. Far from the typical 'meet-and-greet' exhibition/conference you experience as a sponsor or exhibitor here you will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

## Benefits of Partnering


The greatest IP minds from across the globe join as conference speakers and discuss the nuances of pharma IP



Be a part of the region's largest pharma IP event which opens its doors to the biggest Pharma Companies



An explosion of business opportunities which can be explored along with displaying thought-leadership at the conference



Enhanced brand visibility which begins before the event through visibility on the event's digital platform. Customised partnership opportunities which allow you to establish rapport with the IP professionals onsite



# SPEAKERS



**Dr B K Sahu,**  
Sr Regional Manager and  
Head (IPFC & TISC),  
**National Research Development  
Corporation (DSIR Enterprise,  
Ministry of S&T, Govt. of India)**



**Dr. B P Singh,**  
Former Chairman In-Charge &  
Technical Member-Patents  
Intellectual Property Appellate  
Board (IPAB) Department for  
Promotion of Industry and  
Internal Trade,  
**Ministry of Commerce and  
Industry, Government of India.**



**Dr. Amar Desai**  
General Manager - Global IP,  
**Zydus Cadila**



**Dr. Harish Chandran Avaronnan,**  
Head of Intellectual Property, India,  
**Novozymes**



**Dr. Paras Vasanani**  
Head & Associate Vice President-  
Business Development,  
Portfolio & Strategy,  
**Kashiv BioSciences LLC**



**Dr. Vivek Mittal**  
Global General Counsel  
**Dr. Reddy's Laboratories**



**Dr. Patnala Sri Ramachandra Murth**  
Director, Head - IPR department,  
**Neuland Laboratories Limited**



**Gautam Bakshi,**  
Head & Patent Counsel Intellectual  
Property Management,  
**Unichem labs**



**John Cabeca,**  
United States Intellectual Property  
Counselor for South Asia,  
**United States Department of  
Commerce**




**Prachi Tiwari,**  
Sr. Director (Head) – IP,  
**Fresenius Kabi**



**Srinivasa Reddy Madduri,**  
Vice President & Head – Global  
Portfolio, BD & IP,  
**Granules India Limited**



**Nevin Koshy,**  
Partner and Head IP of Patent –  
Design - Copyright Department,  
**United Trademark & Patent  
Services**



**Timothy H. Kratz**  
Partner  
**Kratz & Barry LLP**



**Edward D. Pergament**  
Founding Partner  
**Esq., Pergament & Cepeda LLP,**

# SPEAKERS



**Steven M. Coyle,**  
Partner,  
Co-Chair Pharmaceutical Practice,  
Co-Chair Litigation Practice,  
**Cantor Colburn LLP**



**Christopher J. Harnett**  
Shareholder  
**Maynard Cooper & Gale**



**Christopher T. Griffith**  
Founding Partner  
**Green Griffith**



# AGENDA | Day - 1

08:30	<b>REGISTRATION AND REFRESHMENTS</b>
09:50	Welcome address and Inauguration
	<b>USA</b>
10:00	<b>Opening Keynote -</b> - John Cabeca, United States Intellectual Property Counselor for South Asia, United States Department of Commerce
10:20	<b>Addressing on the growing debate over Skinny labeling for Generic Drugs</b>
10:40	<b>Increasing your chance of success in a Bet-in-company pharma litigation</b> <ul style="list-style-type: none"><li>• Identifying the processes and criteria's for selecting the best witnesses</li><li>• Tools for success in direct and cross examination</li></ul>
11:00	<b>NETWORKING REFRESHMENTS</b>
11:30	<b>The Future of Section 112 Patent Defenses in Hatch-Waxman Litigation</b> - Timothy H. Kratz, Partner, Kratz & Barry LLP
12:00	<b>Due diligence Panel discussion Managing the IPR due diligence process in your organization</b> <ul style="list-style-type: none"><li>• Quantifying the value of the IP at stake in the deal for both the business and legal teams</li><li>• Uncovering and resolving hidden issues with ownership rights, inventorship, and obligations under prior contractual agreements</li></ul> <b>Panel members</b> <ul style="list-style-type: none"><li>- John Cabeca, United States Intellectual Property Counselor for South Asia, United States Department of Commerce</li><li>- Dr. Vivek Mittal Global General Counsel Dr. Reddy's Laboratories</li></ul>
12:40	<b>Reviewing legal developments on the question of whether AI or technology can be an inventor and the implications for life sciences companies employing AI technologies</b> <ul style="list-style-type: none"><li>• An overview on the DABUS case</li><li>- Gautam Bakshi, Head &amp; Patent Counsel Intellectual Property Management, Unichem labs</li></ul>
13:00	<b>Examining supreme court decision in line with assignor estoppel</b> - Steven M. Coyle, Partner, Co-Chair Pharmaceutical Practice, Co-Chair Litigation Practice, Cantor Colburn LLP
13:30	<b>NETWORKING LUNCH</b>
14:30	<b>A practical approach to Freedom To Operate (FTO) for better innovations and negotiations</b> <ul style="list-style-type: none"><li>• Understanding where and how patent infringement risks lie</li><li>• How to manage those risks prior to commercialization</li><li>- Edward D. Pergament, Owner, Pergament &amp; Cepeda LLP</li></ul>
15:00	<b>Examining supreme court decision in line with assignor estoppel</b> <ul style="list-style-type: none"><li>• Narrowing of its scope &amp; limitations placed by court</li><li>• Future application</li></ul>
15:30	<b>Panel Discussion - strategies for successfully obtaining secondary patents and extending patent life</b> <ul style="list-style-type: none"><li>• Analyzing evolution of the law &amp; jurisprudence</li><li>• Exploring claim drafting in view of label carve outs</li><li>• Understanding best practices in building a strong and diverse secondary patent portfolio</li></ul> <b>Panel members</b> <ul style="list-style-type: none"><li>- Timothy H. Kratz, Partner, Kratz &amp; Barry LLP</li><li>- Gautam Bakshi, Head &amp; Patent Counsel Intellectual Property Management, Unichem labs</li><li>- Dr. B P Singh, Former Chairman In-Charge &amp; Technical Member-Patents Intellectual Property Appellate Board (IPAB) Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry, Government of India.</li></ul>
16:30	<b>NETWORKING REFRESHMENTS</b>
17:00	<b>Mergers &amp; acquisition and expanded jurisdiction</b> <ul style="list-style-type: none"><li>• Considering the different acquisition, formation and contribution models and identifying the model best suited for each company's goals</li><li>• Reviewing the next steps following the IP due diligence opinion</li><li>- Dr. Vivek Mittal Global General Counsel Dr. Reddy's Laboratories</li></ul>
17:30	<b>Ethical dilemmas that arise in Pharma IP due diligence: Key strategies for identification and prevention</b> <ul style="list-style-type: none"><li>• Inequitable conduct and duties of candor to courts, tribunals, and the USPTO</li><li>• Communications with represented parties</li><li>• How to work with outside counsel to avoid contamination</li></ul>
18:00	<b>Emerging Issues in US law on antibody and life sciences patents</b> <ul style="list-style-type: none"><li>• Ensure effective protection for your antibody's portfolio</li></ul>
18:30	<b>Cocktail Opening Address</b>

# AGENDA | Day - 2

09:00

## REGISTRATION AND REFRESHMENTS

10:00

### Key focus on winning patent litigation strategies

- Use case laws on law on obviousness, inherent obviousness, and OTPD
- Claims of sufficiency
- Insufficiency by ambiguity
- Doctrine of equivalents
- Christopher J. Harnett, Shareholder, Maynard Cooper & Gale
- Christopher T. Griffith, Founding Partner, Green Griffith

10:30

### Panel Discussion: Biosimilars – IP strategy for biosimilar manufacturers

- Navigating secondary patents
- Registering own IP rights
- Licensing opportunities

11:30

## NETWORKING REFRESHMENTS

### EUROPE

12:00

### Examining the status of Unitary Patent (UP) & Unified Patent Court (UPC)

- Update on preparatory activities a what to expect in near future

12:30

### Review of latest preliminary injunctions cases and their impact on litigation strategies

- Discuss whether a claim for reasonable compensation from the person or entity that “infringed” the patent before it was granted is available?
- Understand how German case law was considered as running contrary to EU Enforcement Directive, Directive 2004/48/EC.

13:00

### Technical tools for drafting and claiming antibodies in view of developing case law in Europe

- The latest strategies for successfully claiming antibody patents and epitopes in Europe

13:30

## NETWORKING LUNCH

14:30

### Building effective use of supplementary protection certificate (SPC)

- CJEU Case Law on art 3(a)

15:00

### Clinical trial disclosure and IP rights - Overcoming the obstacles to patentability in Europe

- Understanding the risk of prior art disclosure
- Recommendations to avoid clinical trials becoming an obstructions to patentability in Europe

15:30

### Shifting towards EUIPO ADR mechanisms

- Alternative Dispute Resolution Proceedings for Pharma and Biotech Patent Disputes

16:00

## NETWORKING REFRESHMENTS

### REST OF THE WORLD

16:00

#### SOUTHEAST ASIA

Implications of medicine patent pool & patent extension

16:30

#### MIDDLE EAST

E-labelling Initiatives in the GCC & Africa

- Focus on key MEA e-labeling initiatives

17:00

#### LATIN AMERICA

Overview of pharma IP & competition law in Latin America

- Mexican patent linkage system: present and future
- Understanding mechanisms for patent term adjustment

17:00

#### AUSTRALASIA

Current developments and challenges in Australia and New Zealand

18:00

## Cocktail Opening Address

# AGENDA | Day - 3

09:00 REGISTRATION AND REFRESHMENTS



INDIA

10:00 **Panel Discussion: Evolving patent landscape in India**  
• Assessing case laws on infringements and compulsory licensing  
• Indian pharma outlook towards growing R&D

11:00 **Reviewing the application of skinny labelling for the Indian market**  
• Implications for the generics market and the practice of skinny labeling

11:30 NETWORKING REFRESHMENTS

13:00 **Panel Discussion: Key steps to keep in mind for your ANDA & BLA filing**  
• Overview of the revised drug guidance including BE & Pharmacokinetics endpoints for drug submission

14:00 **Panel Discussion: Patent Infringement and damages claim**  
• Best practices to resolve litigations & claim damages on licensing and explore alternatives to litigation like mediation and other win-win options

14:00 NETWORKING LUNCH & END OF THE CONFERENCE

# PAST EVENT PARTNERS



and many more...

## PLATINUM PARTNER



## SILVER PARTNERS



Cantor Colburn LLP



EUROPEAN PATENT AND  
TRADEMARK ATTORNEYS

AA THORNTON  
INTELLECTUAL PROPERTY LAW



## BRONZE PARTNERS



MAYNARD  
COOPER GALE

Green Griffith  
Intellectual Property Law

## MEDIA PARTNER



## CONTACT

FOR PARTNERSHIPS, EXHIBIT & SPEAKING OPPORTUNITIES

**Sanjana Periera**

M: +91 98216 96027

E: [sanjana.pereira@informa.com](mailto:sanjana.pereira@informa.com)

FOR MARKETING & ALLIANCES:

**Pratibha Gupta**

M: +91 8879215939

E: [pratibha.gupta.in@informa.com](mailto:pratibha.gupta.in@informa.com)



Informa Markets India Private Limited, 1st Floor B wing, Unit No 3 and 4, Solitaire XIV,  
Guru Hargovindji Marg, Chakala, Andheri East, Mumbai Suburban, Maharashtra, 400093